# Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer

> **NCT06204094** · PHASE2 · RECRUITING · sponsor: **Jinhua Central Hospital** · enrollment: 37 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer

## Interventions

- **RADIATION:** node-sparing short-course radiotherapy
- **DRUG:** Sintilimab
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **PROCEDURE:** TME surgery
- **PROCEDURE:** watch and wait

## Key facts

- **NCT ID:** NCT06204094
- **Lead sponsor:** Jinhua Central Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-05
- **Primary completion:** 2027-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06204094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06204094, "Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06204094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*